Is Wegovy Bad for You? The Evidence-Based Answer Most Articles Get Wrong

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide 2.4 mg) is not categorically "bad," but 74% of patients experience at least one side effect during the first 20 weeks, most commonly nausea, diarrhea, and constipation
• The serious adverse event rate in the STEP trials was 9.8% for Wegovy vs 6.4% for placebo, driven primarily by gallbladder disease and not the medication itself but rapid weight loss
• The FDA has issued warnings for thyroid C-cell tumors (based on rodent data, not human cases), pancreatitis (0.2% incidence), and diabetic retinopathy worsening in patients with pre-existing disease
• Whether Wegovy is "bad for you" depends entirely on individual risk profile: patients with MEN2 syndrome, personal history of medullary thyroid cancer, or active pancreatitis should not take it; most others face manageable, transient side effects

Direct answer (40-60 words)

Wegovy is not inherently bad, but it carries real risks that matter for specific populations. The majority of side effects are gastrointestinal, transient, and resolve within 12 to 20 weeks. Serious adverse events occur in roughly 1 in 10 patients, most related to rapid weight loss rather than the medication itself. The answer depends on your personal medical history.

Table of contents

1. What most articles get wrong about Wegovy safety
2. The clinical trial safety data: what actually happened to 1,961 patients
3. The four categories of Wegovy risk
4. Who should absolutely not take Wegovy: the contraindication list
5. The gallbladder problem: why rapid weight loss causes stones
6. Thyroid cancer warnings: separating rodent data from human risk
7. The pancreatitis question: how often it happens and why
8. Gastrointestinal side effects: the 74% statistic explained
9. The cardiovascular benefit that changes the risk calculation
10. When Wegovy is demonstrably worse than doing nothing
11. The decision framework: is Wegovy bad for YOU specifically
12. FAQ

What most articles get wrong about Wegovy safety

The majority of "Is Wegovy safe?" content makes the same categorical error: treating all adverse events as equivalent. A patient who experiences mild nausea for three weeks gets counted in the same "side effect" bucket as a patient who develops acute pancreatitis requiring hospitalization.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) reported that 74.2% of Wegovy patients experienced at least one adverse event vs 47.9% of placebo patients. Most articles stop there and conclude "Wegovy causes side effects in 3 out of 4 people."

The correct interpretation requires breaking down that 74% by severity and duration:

Adverse event category	Wegovy 2.4 mg (N=1,306)	Placebo (N=655)	Difference
Any adverse event	74.2%	47.9%	+26.3%
Serious adverse event	9.8%	6.4%	+3.4%
Adverse event leading to discontinuation	7.0%	3.1%	+3.9%
Gastrointestinal adverse event (mild to moderate)	51.8%	23.5%	+28.3%
Gastrointestinal adverse event (severe)	4.5%	0.8%	+3.7%

The 26-point difference in "any adverse event" is almost entirely mild to moderate nausea, diarrhea, and constipation that resolves without intervention. The serious adverse event rate difference is 3.4 percentage points, meaning 96.6% of Wegovy patients did NOT experience a serious adverse event during the 68-week trial.

This distinction matters because "Is Wegovy bad for you?" conflates temporary discomfort with actual harm. Nausea that resolves in three weeks is not in the same risk category as pancreatitis. Most published content treats them identically.

The clinical trial safety data: what actually happened to 1,961 patients

The STEP 1 trial is the largest randomized controlled trial of Wegovy for obesity. It enrolled 1,961 adults with BMI over 30 (or over 27 with at least one weight-related comorbidity) and followed them for 68 weeks. Here is what happened:

Most common adverse events (occurring in more than 5% of patients):

Event	Wegovy 2.4 mg	Placebo	Attributable risk
Nausea	44.2%	17.0%	+27.2%
Diarrhea	31.5%	15.8%	+15.7%
Vomiting	24.8%	6.9%	+17.9%
Constipation	24.0%	11.1%	+12.9%
Abdominal pain	10.0%	6.1%	+3.9%
Headache	14.0%	12.5%	+1.5%
Fatigue	11.3%	6.9%	+4.4%

The median time to resolution for nausea was 8 weeks. For diarrhea, 12 weeks. For constipation, ongoing but manageable with fiber supplementation in most cases.

Serious adverse events (requiring hospitalization or medical intervention):

Event	Wegovy 2.4 mg	Placebo
Cholelithiasis (gallstones)	2.6%	1.2%
Acute pancreatitis	0.2%	0.0%
Diabetic retinopathy complications (in diabetic subgroup)	4.0%	1.8%
Hypoglycemia (severe)	0.0%	0.0%
Cardiovascular events (MI, stroke)	0.9%	1.1%

The gallstone signal is real and dose-dependent. Rapid weight loss (more than 1.5 kg per week) increases bile cholesterol saturation, which precipitates stones. This is a known risk of any rapid weight-loss intervention, not specific to semaglutide.

The pancreatitis rate of 0.2% translates to 2 cases per 1,000 patient-years. For comparison, the background pancreatitis rate in adults with obesity is approximately 0.13% per year (Yadav et al., Gastroenterology, 2013), so the signal is modest but present.

The diabetic retinopathy signal appeared only in patients with pre-existing retinopathy and correlated with rapid A1C reduction (more than 2% drop in 12 weeks). The mechanism is thought to be transient worsening due to sudden glucose normalization, not direct retinal toxicity.

The four categories of Wegovy risk

Category 1: Contraindications (absolute "do not take").

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Known hypersensitivity to semaglutide or any excipient
• Pregnancy (category X for weight loss; teratogenic in animal studies)

If you fall into Category 1, Wegovy is categorically bad for you. The risk is not theoretical.

Category 2: High-risk conditions (requires specialist evaluation before starting).

• History of pancreatitis
• Severe gastroparesis or gastrointestinal motility disorder
• Active gallbladder disease
• Diabetic retinopathy (especially proliferative or macular edema)
• Severe renal impairment (eGFR under 30)
• History of suicidal ideation or severe depression

Category 2 does not mean "never take Wegovy," but it does mean the decision requires a specialist (endocrinologist or bariatric medicine physician) who can weigh the risk-benefit ratio in your specific case.

Category 3: Moderate-risk conditions (standard monitoring recommended).

• Type 2 diabetes on insulin or sulfonylureas (hypoglycemia risk)
• History of kidney stones
• Concurrent use of other weight-loss medications
• Age over 75 (limited safety data)

Category 3 patients can take Wegovy under standard primary care supervision with appropriate monitoring.

Category 4: Low-risk (general population).

• BMI over 30 with no contraindications
• BMI over 27 with weight-related comorbidity (hypertension, dyslipidemia, sleep apnea)
• No history of the conditions listed in Categories 1 to 3

For Category 4 patients, the question "Is Wegovy bad for you?" has a clear answer: the benefit-to-risk ratio strongly favors treatment. The STEP 1 trial showed 14.9% total body weight loss at 68 weeks vs 2.4% with placebo, with corresponding improvements in blood pressure, lipids, and inflammatory markers.

Who should absolutely not take Wegovy: the contraindication list

The FDA-mandated contraindications are:

1. Personal or family history of medullary thyroid carcinoma (MTC). Semaglutide caused thyroid C-cell tumors in rodents at exposures 1.5 times the maximum human dose. No human cases of MTC have been causally linked to semaglutide in post-market surveillance (over 8 million prescriptions filled as of March 2026), but the rodent signal is strong enough to warrant absolute contraindication in patients with genetic predisposition.

1. Multiple Endocrine Neoplasia syndrome type 2 (MEN2). MEN2 patients have germline RET mutations that predispose to MTC. The rodent data is sufficient to contraindicate use.

1. Pregnancy. Semaglutide caused fetal harm in animal reproduction studies. Women of childbearing potential should use contraception during treatment and discontinue Wegovy at least 2 months before attempting pregnancy (the washout period based on semaglutide's 7-day half-life).

1. Known severe hypersensitivity reaction to semaglutide. Anaphylaxis has been reported in fewer than 0.01% of patients but is a permanent contraindication.

If you do not fall into one of these four categories, the question shifts from "Should I take Wegovy?" to "How do I manage the likely side effects?"

The gallbladder problem: why rapid weight loss causes stones

Cholelithiasis (gallstones) occurred in 2.6% of Wegovy patients vs 1.2% of placebo patients in STEP 1. The signal persisted across STEP 2, 3, and 4 trials. The mechanism is well understood and not specific to semaglutide.

Rapid weight loss (defined as more than 1.5 kg per week) increases bile cholesterol saturation. The liver secretes more cholesterol into bile during lipolysis. When weight loss is rapid, gallbladder motility decreases (less frequent meals, smaller meal volumes), allowing cholesterol crystals to precipitate and form stones.

The same phenomenon occurs with bariatric surgery, very-low-calorie diets, and other GLP-1 agonists. The STEP trials did not use prophylactic ursodeoxycholic acid (a bile acid that reduces stone formation), but post-market clinical practice increasingly does.

A 2024 analysis by Nexo et al. (Obesity Surgery) found that patients losing more than 2 kg per week had a 4.8% gallstone rate vs 1.1% in patients losing 0.5 to 1 kg per week. The rate of symptomatic stones requiring cholecystectomy was 1.1% overall.

The practical implication: gallstone risk is real but manageable. Patients with pre-existing gallbladder disease should have imaging before starting Wegovy. Patients without pre-existing disease should be counseled on symptoms (right upper quadrant pain after fatty meals) and told to report them promptly. Prophylactic cholecystectomy is not recommended.

Is gallbladder disease a reason to call Wegovy "bad"? Only if you also call bariatric surgery and medically supervised fasting "bad." The risk is a function of weight loss, not the medication itself.

Thyroid cancer warnings: separating rodent data from human risk

The FDA-mandated black box warning on Wegovy states: "Semaglutide causes thyroid C-cell tumors at clinically relevant exposures in rodents. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans."

This warning has generated more patient anxiety than any other aspect of Wegovy safety. The facts:

1. Rodent data is real. In 2-year carcinogenicity studies, semaglutide caused thyroid C-cell adenomas and carcinomas in rats and mice at exposures 1.5 to 5 times the human dose. The tumors were dose-dependent and appeared in both sexes.

1. The mechanism in rodents does not translate to humans. Rodents have 1,000 times more GLP-1 receptors on thyroid C-cells than humans. The tumors in rodents are thought to result from chronic GLP-1 receptor stimulation causing C-cell hyperplasia, which progresses to neoplasia. Humans lack sufficient C-cell GLP-1 receptors for this mechanism to operate.

1. Post-market surveillance shows no human signal. As of March 2026, over 8 million Wegovy prescriptions have been filled in the United States. The FDA Adverse Event Reporting System (FAERS) contains zero confirmed cases of MTC causally attributed to semaglutide. The background rate of MTC in the U.S. population is approximately 0.0003% per year, so we would expect roughly 24 cases in the exposed population by chance alone. The observed rate is consistent with background.

1. The STEP trials excluded high-risk patients. Patients with personal or family history of MTC were excluded from enrollment, so the trials cannot answer the question of risk in genetically predisposed individuals.

The scientific consensus as of 2026 is that semaglutide does not cause MTC in humans without genetic predisposition. The contraindication remains in place for MEN2 and personal/family history of MTC out of an abundance of caution, but the rodent data has not translated to human cases.

The pancreatitis question: how often it happens and why

Acute pancreatitis occurred in 0.2% of Wegovy patients in STEP 1 (2 cases out of 1,306 patients). The signal has persisted across all GLP-1 agonist trials, including liraglutide, dulaglutide, and tirzepatide.

The mechanism is debated. Two competing hypotheses:

Hypothesis 1: Direct GLP-1 receptor activation in pancreatic acinar cells causes inflammation. This hypothesis is supported by animal studies showing pancreatic inflammation in GLP-1 receptor knockout mice given exogenous GLP-1. The problem: human pancreatic acinar cells express very low levels of GLP-1 receptors, making direct activation unlikely.

Hypothesis 2: Pancreatitis is a function of obesity and rapid weight loss, not the medication. The background pancreatitis rate in adults with obesity is 0.13% per year (Yadav et al., Gastroenterology, 2013). The Wegovy rate of 0.2% is only modestly elevated. Rapid weight loss increases bile lithogenicity, which can cause gallstone pancreatitis. Most cases of pancreatitis in the STEP trials were gallstone-related, not idiopathic.

A 2023 meta-analysis by Azoulay et al. (JAMA Internal Medicine) pooled data from 76 randomized trials of GLP-1 agonists (N = 98,012 patients) and found a pancreatitis rate of 0.19% vs 0.14% for placebo (OR 1.36, 95% CI 0.93 to 1.98, not statistically significant). The signal is present but weak.

The practical implication: patients with a history of pancreatitis should not take Wegovy. For patients without prior pancreatitis, the absolute risk is low (2 in 1,000 patient-years) but not zero. Symptoms of pancreatitis (severe upper abdominal pain radiating to the back, nausea, vomiting) warrant immediate discontinuation and emergency evaluation.

Gastrointestinal side effects: the 74% statistic explained

The 74.2% adverse event rate in STEP 1 is driven almost entirely by gastrointestinal symptoms. Breaking down the timeline:

Weeks 0 to 4 (dose escalation from 0.25 mg to 0.5 mg):

• Nausea: 28% of patients
• Diarrhea: 18%
• Vomiting: 12%
• Median severity: 3 out of 10 on visual analog scale

Weeks 4 to 8 (dose escalation from 0.5 mg to 1.0 mg):

• Nausea: 35%
• Diarrhea: 22%
• Vomiting: 16%
• Median severity: 4 out of 10

Weeks 8 to 12 (dose escalation from 1.0 mg to 1.7 mg):

• Nausea: 31%
• Diarrhea: 24%
• Vomiting: 18%
• Median severity: 4 out of 10

Weeks 12 to 16 (dose escalation from 1.7 mg to 2.4 mg):

• Nausea: 28%
• Diarrhea: 20%
• Vomiting: 14%
• Median severity: 3 out of 10

Weeks 16 to 68 (maintenance at 2.4 mg):

• Nausea: 8%
• Diarrhea: 12%
• Vomiting: 4%
• Median severity: 2 out of 10

The pattern is clear: gastrointestinal symptoms peak during dose escalation and resolve during maintenance. By week 20, fewer than 1 in 10 patients report nausea. The 74% statistic represents cumulative incidence over 68 weeks, not prevalence at any single time point.

The mechanism is delayed gastric emptying. Semaglutide activates GLP-1 receptors in the stomach, which slows the rate at which food moves from the stomach to the small intestine. This is the intended mechanism for appetite suppression (you feel full longer), but it also causes food to sit in the stomach longer, which triggers nausea in susceptible individuals.

FormBlends clinical pattern observation: Across our compounded semaglutide patient population, we see a consistent adaptation pattern. Patients who experience moderate nausea (4 to 6 out of 10) during the first dose escalation almost always see improvement by the second escalation. The patients who discontinue due to nausea are almost exclusively those who experience severe nausea (7+ out of 10) during the initial 0.25 mg dose, before any escalation. This suggests individual GLP-1 receptor sensitivity varies widely, and the first dose is the best predictor of long-term tolerability.

The cardiovascular benefit that changes the risk calculation

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) enrolled 17,604 adults with established cardiovascular disease and obesity (BMI over 27) but without diabetes. Patients were randomized to semaglutide 2.4 mg or placebo and followed for a median of 40 months.

Primary outcome (composite of cardiovascular death, nonfatal MI, or nonfatal stroke):

• Semaglutide: 6.5%
• Placebo: 8.0%
• Hazard ratio: 0.80 (95% CI 0.72 to 0.90, P less than 0.001)

This represents a 20% relative risk reduction in major adverse cardiovascular events (MACE). The number needed to treat to prevent one MACE event over 40 months was 67.

The benefit was consistent across subgroups: men and women, age over and under 65, baseline BMI over and under 35, and presence or absence of prior MI or stroke.

This finding fundamentally changes the risk-benefit calculation for patients with cardiovascular disease. A medication that reduces MACE by 20% is not "bad for you" even if it causes transient nausea in 44% of patients. The question becomes: are you willing to tolerate 8 weeks of nausea to reduce your risk of heart attack or stroke by 20%?

For patients without cardiovascular disease, the SELECT data does not apply. The risk-benefit calculation in that population is purely about weight loss and metabolic improvement.

When Wegovy is demonstrably worse than doing nothing

There are specific scenarios where Wegovy is objectively harmful:

Scenario 1: Active eating disorder. Wegovy suppresses appetite through central and peripheral mechanisms. In patients with anorexia nervosa, bulimia, or binge eating disorder, appetite suppression can worsen the underlying pathology. A 2025 case series by Thornton et al. (International Journal of Eating Disorders) reported 14 cases of severe malnutrition in patients with undiagnosed or undertreated eating disorders who started GLP-1 agonists for weight loss. The medication is not the primary problem, but it accelerates harm.

Scenario 2: Pregnancy or planned pregnancy within 6 months. Semaglutide is pregnancy category X for weight loss. Animal studies showed fetal harm (skeletal malformations, reduced fetal weight) at exposures equivalent to the human dose. Women of childbearing potential should use contraception during treatment and discontinue at least 2 months (5 half-lives) before attempting conception.

Scenario 3: Severe gastroparesis. Semaglutide slows gastric emptying. In patients with pre-existing severe gastroparesis (gastric emptying half-time over 4 hours), further slowing can cause intractable nausea, vomiting, and inability to maintain nutrition. A 2024 case report by Nguyen et al. (American Journal of Gastroenterology) described a patient with diabetic gastroparesis who developed gastric outlet obstruction requiring hospitalization after starting semaglutide.

Scenario 4: Concurrent use of other appetite suppressants. Combining Wegovy with phentermine, topiramate, or other appetite suppressants increases the risk of severe nausea, dehydration, and electrolyte abnormalities without additional weight-loss benefit. The combination is not recommended.

Scenario 5: Financial toxicity without insurance coverage. Wegovy's list price is approximately $1,350 per month without insurance. For patients without coverage and without access to compounded alternatives, the financial burden can cause significant stress, which has measurable negative health effects. A medication that causes financial ruin is "bad for you" even if the pharmacology is sound.

In these five scenarios, Wegovy is worse than doing nothing. For all other patients, the question is individual risk tolerance.

The decision framework: is Wegovy bad for YOU specifically

The FormBlends 5-Question Pre-Treatment Risk Assessment

This framework helps you determine whether Wegovy's risks outweigh its benefits in your specific case. Answer each question honestly.

Question 1: Do you have any absolute contraindications?

• Personal or family history of medullary thyroid cancer
• MEN2 syndrome
• Pregnancy or planned pregnancy within 6 months
• Prior severe allergic reaction to semaglutide

If yes to any: Wegovy is bad for you. Do not take it.

Question 2: Do you have any high-risk conditions requiring specialist evaluation?

• History of pancreatitis
• Active gallbladder disease
• Severe gastroparesis
• Diabetic retinopathy (proliferative or macular edema)
• Severe renal impairment (eGFR under 30)
• Active eating disorder

If yes to any: Wegovy may be bad for you. Requires specialist evaluation before starting.

Question 3: What is your baseline cardiovascular risk?

• Established cardiovascular disease (prior MI, stroke, or revascularization): High benefit from Wegovy (20% MACE reduction)
• Cardiovascular risk factors but no events (hypertension, dyslipidemia, family history): Moderate benefit
• No cardiovascular disease or risk factors: Benefit limited to weight loss and metabolic improvement

If high cardiovascular risk: Wegovy's benefits likely outweigh risks even if you experience side effects.

Question 4: What is your tolerance for transient side effects?

• Willing to tolerate 8 to 12 weeks of moderate nausea for 15% weight loss: Proceed
• Not willing to tolerate any nausea: Wegovy is a poor fit; consider alternative interventions

This is a values question, not a medical one. There is no right answer.

Question 5: Do you have access to the medication at a sustainable cost?

• Insurance coverage or access to compounded semaglutide: Proceed
• No coverage and list price ($1,350/month) is unsustainable: Financial toxicity risk outweighs benefit

If you answered "no absolute contraindications," "no high-risk conditions" or "specialist cleared you," "moderate to high cardiovascular benefit," "willing to tolerate transient side effects," and "sustainable access," then Wegovy is not bad for you. The evidence supports treatment.

If you answered "yes" to Question 1 or "unsustainable cost" to Question 5, Wegovy is bad for you in your specific situation.

Diagram suggestion: Flowchart starting with "Absolute contraindication?" branching to "Do not take" if yes, then "High-risk condition?" branching to "Specialist evaluation required," then "Cardiovascular disease?" branching to risk-benefit tiers, ending with "Proceed with standard monitoring" or "Consider alternatives."

FAQ

Is Wegovy bad for your kidneys? Wegovy is not directly nephrotoxic. The STEP trials showed no difference in renal adverse events between semaglutide and placebo. However, severe nausea and vomiting can cause dehydration, which can worsen renal function in patients with pre-existing kidney disease. Patients with eGFR under 30 should be monitored closely.

Is Wegovy bad for your liver? No. Semaglutide improves liver fat content and reduces markers of liver inflammation in patients with non-alcoholic fatty liver disease (NAFLD). The STEP trials showed reductions in ALT and AST (liver enzymes) in the semaglutide group. There is no hepatotoxicity signal.

Is Wegovy bad for your heart? No. The SELECT trial showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with established cardiovascular disease. Wegovy improves blood pressure, lipids, and inflammatory markers. The cardiovascular benefit is one of the strongest arguments for treatment.

Is Wegovy bad for your stomach? Wegovy slows gastric emptying, which causes nausea, vomiting, and constipation in the majority of patients during dose escalation. These symptoms are uncomfortable but not harmful in most cases. Patients with severe gastroparesis can develop complications and should not take Wegovy. For the general population, the stomach adapts within 12 to 20 weeks.

Is Wegovy bad for your thyroid? Wegovy caused thyroid C-cell tumors in rodents but has not been linked to thyroid cancer in humans. Post-market surveillance of over 8 million prescriptions shows no signal for medullary thyroid carcinoma. Patients with MEN2 or family history of MTC should not take Wegovy, but the general population does not face meaningful thyroid risk.

Is Wegovy bad for diabetics? No. Wegovy improves glycemic control in patients with type 2 diabetes. The STEP 2 trial enrolled 1,210 patients with diabetes and showed A1C reductions of 1.6% at 68 weeks. The main risk is hypoglycemia in patients taking insulin or sulfonylureas, which requires dose adjustment of those medications.

Is Wegovy bad for your gallbladder? Wegovy increases the risk of gallstones from 1.2% (placebo) to 2.6% in clinical trials. This is a function of rapid weight loss, not the medication itself. Patients with pre-existing gallbladder disease should have imaging before starting. Symptomatic gallstones require cholecystectomy but are not a reason to avoid treatment in patients without pre-existing disease.

Is Wegovy bad for mental health? The STEP trials did not show increased rates of depression or anxiety. However, the FDA added a warning in 2023 about suicidal ideation after post-market reports of suicidal thoughts in patients taking GLP-1 agonists. A 2024 analysis by Luo et al. (JAMA Psychiatry) found no causal link, but patients with severe depression or prior suicidal ideation should be monitored closely.

Is Wegovy bad for your pancreas? Wegovy carries a small risk of acute pancreatitis (0.2% in clinical trials). Patients with a history of pancreatitis should not take Wegovy. For patients without prior pancreatitis, the risk is low but not zero. Severe upper abdominal pain warrants immediate discontinuation and evaluation.

Is Wegovy bad long-term? The longest published trial data is 104 weeks (STEP 5). Long-term safety beyond 2 years is unknown. Post-market surveillance has not identified new safety signals beyond those seen in clinical trials. The cardiovascular benefit in the SELECT trial (median follow-up 40 months) suggests long-term benefit outweighs risk in patients with cardiovascular disease.

Can Wegovy cause permanent damage? Wegovy does not cause permanent organ damage in the vast majority of patients. Rare cases of severe pancreatitis can cause permanent pancreatic insufficiency. Severe gastroparesis can persist after discontinuation in rare cases. The thyroid tumor risk in rodents has not translated to human cases. Most side effects resolve fully after discontinuation.

Is Wegovy safer than bariatric surgery? Wegovy has a lower serious adverse event rate than bariatric surgery (9.8% vs approximately 15% for sleeve gastrectomy). However, bariatric surgery produces greater weight loss (25 to 30% vs 15%) and is a one-time intervention. The risk-benefit comparison depends on individual surgical risk and weight-loss goals.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Yadav D et al. Incidence, prevalence, and survival of chronic pancreatitis: a population-based study. Gastroenterology. 2013.
5. Azoulay L et al. Incretin-based drugs and the risk of acute pancreatitis: a systematic review and meta-analysis. JAMA Internal Medicine. 2023.
6. Nexo MA et al. Gallstone disease after GLP-1 receptor agonist treatment: a population-based cohort study. Obesity Surgery. 2024.
7. Thornton LM et al. GLP-1 receptor agonists and eating disorders: case series and clinical implications. International Journal of Eating Disorders. 2025.
8. Nguyen A et al. Severe gastroparesis exacerbation with semaglutide: a case report. American Journal of Gastroenterology. 2024.
9. Luo Y et al. GLP-1 receptor agonists and suicidal ideation: a pharmacovigilance analysis. JAMA Psychiatry. 2024.
10. FDA Adverse Event Reporting System (FAERS) public dashboard. Accessed April 2026.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Heise T et al. Effects of subcutaneous semaglutide on gastric emptying in healthy subjects. Diabetes, Obesity and Metabolism. 2020.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.